10x Genomics (TXG) Expected to Announce Earnings on Thursday

10x Genomics (NASDAQ:TXG) is expected to post its Q4 2025 results after the market closes on Thursday, February 12th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $160.3520 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 12, 2026 at 4:30 PM ET.

10x Genomics Trading Down 0.4%

10x Genomics stock opened at $18.54 on Tuesday. 10x Genomics has a 12-month low of $6.78 and a 12-month high of $23.56. The firm has a market capitalization of $2.35 billion, a price-to-earnings ratio of -29.90 and a beta of 2.24. The firm has a 50 day moving average of $18.63 and a 200 day moving average of $15.50.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on TXG. Zacks Research cut shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $20.00 target price (up previously from $17.00) on shares of 10x Genomics in a report on Monday, December 1st. Barclays raised their price target on 10x Genomics from $17.00 to $22.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 10x Genomics in a research note on Monday, December 22nd. Finally, JPMorgan Chase & Co. lifted their target price on 10x Genomics from $13.00 to $15.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Four investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $16.83.

Insider Transactions at 10x Genomics

In other 10x Genomics news, insider Benjamin J. Hindson sold 8,283 shares of 10x Genomics stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $19.00, for a total value of $157,377.00. Following the sale, the insider owned 432,605 shares of the company’s stock, valued at $8,219,495. The trade was a 1.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Serge Saxonov sold 13,261 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $19.00, for a total value of $251,959.00. Following the sale, the chief executive officer directly owned 1,021,556 shares in the company, valued at $19,409,564. This trade represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 33,432 shares of company stock valued at $635,208. 10.03% of the stock is currently owned by insiders.

Institutional Investors Weigh In On 10x Genomics

Hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC grew its stake in shares of 10x Genomics by 241.3% in the 2nd quarter. AQR Capital Management LLC now owns 4,137,801 shares of the company’s stock worth $47,916,000 after buying an additional 2,925,372 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of 10x Genomics by 84.7% in the 3rd quarter. Millennium Management LLC now owns 5,437,969 shares of the company’s stock valued at $63,570,000 after acquiring an additional 2,494,142 shares during the last quarter. Wellington Management Group LLP grew its position in 10x Genomics by 126.6% in the third quarter. Wellington Management Group LLP now owns 4,285,628 shares of the company’s stock worth $50,099,000 after acquiring an additional 2,394,355 shares in the last quarter. Quantinno Capital Management LP grew its position in 10x Genomics by 207.2% in the second quarter. Quantinno Capital Management LP now owns 2,233,526 shares of the company’s stock worth $25,864,000 after acquiring an additional 1,506,530 shares in the last quarter. Finally, Man Group plc increased its stake in 10x Genomics by 484.9% during the second quarter. Man Group plc now owns 829,610 shares of the company’s stock worth $9,607,000 after acquiring an additional 687,773 shares during the last quarter. Hedge funds and other institutional investors own 84.68% of the company’s stock.

About 10x Genomics

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.